ORIC vs RPC Comparison

ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.

Ridgepost Capital Inc, formelrly P10 Inc is a player in the alternative asset management sector, specializing in multi-asset class private market solutions. It offers a range of investment solutions, including specialized funds, separate accounts, secondary investments, direct investments, and co-investments across various asset classes and geographies. These solutions cater to diverse investor needs within the private markets, aiming to deliver superior risk-adjusted returns. With a focus on middle and lower-middle markets, the company's portfolio includes Private Equity, Venture Capital, Impact Investing, and Private Credit. Its Revenue mainly comes from recurring management and advisory fees earned on committed capital, typically locked up for ten to fifteen years.